Nick Ayton
Boards are being asked to make irreversible bets on AI, quantum, and biotech without a credible internal voice on where these technologies are actually heading. The instinct is to delegate the question to consultants who repeat last year’s consensus. That leaves the most consequential decisions with leaders who lack the horizon to judge them.
Nick Ayton is a futurist and ten-time tech founder who helps boards, investors, and family offices read the commercial implications of AI, quantum computing, and longevity science, and diagnose why otherwise healthy businesses lose cash before the financials show it.
Full Profile
Why organisations work with Nick Ayton
- More than four decades inside computer science and ten founded start-ups give him a working operator’s view of where deep tech actually breaks, not a consultant’s slide on where it might.
- He translates AI, quantum, and longevity science into capital allocation questions a CFO or investment committee can act on, which is rare among futurists who stop at the trend.
- His book The Slow Bleed sets out Cash Conversion Velocity, a diagnostic he uses to show CEOs why a profitable business is draining cash and what to fix first, in days rather than quarters.
- His Living to 150 book and ongoing work on AI-assisted healthcare give him a specific, defensible position on longevity, a topic most technology speakers cannot credibly hold.
- He chairs global summits where deep tech meets investor capital, including the Family Office Summit in Abu Dhabi, so the audience he speaks to most often is the one buyers are trying to reach.
Biography highlights
- Author, The Slow Bleed: A CEO Field Guide to Cash Conversion Velocity (Redline Press, 2026), with a foreword by Ian Wright, founder of VirtualNonExecs.
- Author, Living to 150: A New Era in Personalised AI Healthcare (2024).
- Founder of Crix.io, a regulated crypto-exchange, and Chainstarter Ventures, advising family offices on deep tech investment.
- Named Blockchain Visionary of the Year by Cointelegraph (2018); founding writer of the “Sage of Shoreditch” column.
- Named Top Futurist Speaker at the Family Office Summit, Abu Dhabi (2023).
- Has delivered keynotes and faculty addresses at MIT, Harvard, LSE, and Berkeley, alongside more than 100 global summits, working between the UK and the UAE.
Biography
Most futurist commentary on AI, quantum, and longevity stops at the trend line. Ayton’s work starts where the boardroom question starts: what does this technology mean for the next ten-year capital decision? After more than four decades in computer science and ten founded companies, he speaks to investors and operators in their own language.
His early move into blockchain produced Crix.io, one of the first regulated crypto-exchanges, and the Cointelegraph column that named him Blockchain Visionary of the Year in 2018. The work has since broadened into quantum computing, synthetic biology, and longevity science. His book Living to 150 argues for personalised AI healthcare as the next investable frontier, and he advises family offices on how to position capital around it.
A second strand of his work asks why profitable businesses quietly fail. His 2026 book The Slow Bleed sets out Cash Conversion Velocity, a way to measure the real health of an operating model in days, and a structured programme to fix it in months rather than years. The same instinct runs through his keynotes on why digital transformation so often optimises dysfunction instead of removing it.
What separates Ayton from the futurist field is the audience he was built for. Family offices, founders, and the investment committees behind frontier-tech bets do not want a vision deck. They want someone who has built companies in the category, taken the losses, and can name which signals matter and which numbers lie.
Key speaking topics
- Artificial intelligence and the next decade of enterprise value
- Quantum computing and its commercial timeline
- Data sovereignty and the post-cloud era
- Biological computing and synthetic biology
- Longevity sciences and personalised AI healthcare
- Frontier technology investment for family offices
- Cash Conversion Velocity and operating-model diagnosis
- Why digital transformation fails
Ideal for
- Boards and investment committees making long-horizon capital decisions on AI, quantum, or biotech
- Family offices and private capital allocators positioning around frontier technologies
- Founders and CTOs in deep tech who need a credible external voice on category direction
- CEOs, PE operating partners, and family office principals who suspect a profitable business is quietly losing cash
Audience outcomes
- A clearer read on which deep tech signals carry commercial weight and which are noise
- A working vocabulary for AI, quantum, and longevity that holds up in front of technical and capital audiences
- Specific examples of where capital is already moving in frontier tech, drawn from family office and founder networks
- A way to tell whether a profitable business is actually healthy, using cash conversion rather than the backward-looking metrics on the board pack
- A sharper sense of which technology bets compound over a decade and which expire within two
Talks
How AI is redefining human value faster than institutions can respond, and what that means for labour markets and the leaders trying to manage the transition.
Key takeaways:
- Where AI displaces human work and where it raises the value of human judgement
- What the speed of the shift demands of organisations built to move slowly
- Which assumptions about jobs and skills no longer hold
How the geopolitics of data is ending the cloud era and forcing boards and capital allocators to rethink who controls their infrastructure.
Key takeaways:
- Why the hyperscaler model is fracturing, and what on-prem and sovereign compute restore
- What data sovereignty means for competitive advantage and national security
- How capital is already repositioning around control of infrastructure
Why the next computing paradigm sits at the convergence of biology and AI, and why it is closer to commercial reality than most boards assume.
Key takeaways:
- What biological computation is, and where it outperforms silicon
- Which industries it reshapes first
- Why the timeline is shorter than the consensus view
Why investors consistently misread frontier innovation cycles, and how the gap between capital allocation and technological reality creates systemic blind spots.
Key takeaways:
- Where capital routinely misjudges how mature a technology actually is
- How to tell a genuine inflection point from a hype cycle
Why profitable companies start bleeding cash long before the financials show it, and how Cash Conversion Velocity exposes the decline the dashboard hides.
Key takeaways:
- The single number that reads operating health better than any board pack
- Why almost every metric a board relies on looks backwards
- How to stop the bleed in months rather than years
Why most transformation programmes optimise dysfunction instead of removing it, drawn from more than four decades of evidence, and what to do instead.
Key takeaways:
- Why technology layered onto a broken operating model entrenches the problem
- The questions to ask before funding a transformation programme
- Where to fix the operating model first